A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-designed, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of KH001 in Patients With Dentin Hypersensitivity
Latest Information Update: 18 Mar 2025
At a glance
- Drugs KH 001 HysensBio (Primary)
- Indications Dentin Sensitivity
- Focus Therapeutic Use
- Sponsors HysensBio
- 14 Mar 2025 Status changed from recruiting to completed.
- 22 May 2024 Status changed from not yet recruiting to recruiting.
- 22 Feb 2024 New trial record